A peek at 10x Genomics Inc (TXG): Who has invested in It?

10x Genomics Inc (NASDAQ: TXG) is -13.38% lower on its value in year-to-date trading and has touched a low of $33.79 and a high of $63.57 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The TXG stock was last observed hovering at around $46.05 in the last trading session, with the day’s gains setting it 2.42%.

Currently trading at $48.47, the stock is 10.28% and 0.77% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.26 million and changing 5.26% at the moment leaves the stock -1.26% off its SMA200. TXG registered 0.31% gain for a year compared to 6-month loss of -7.41%. The firm has a 50-day simple moving average (SMA 50) of $9.26 and a 200-day simple moving average (SMA200) of -$30.73.

Invest Like Buffett: Travel Back in Time & Grab This High-Potential Stock Before It Explodes

Imagine buying Apple for $1, Amazon for $2, or Tesla for $3. Now, imagine the same opportunity with a hidden gem trading under $3 right now.

Our premium newsletter, powered by AI and expert analysis, uncovers these time-travel investment opportunities.

Invest like Buffett and profit from undervalued gems before the market catches on.

Limited-time offer: Get your first month for just $2.90 and start your journey to wealth creation.


Sponsored

The stock witnessed a -4.51% gain in the last 1 month and extending the period to 3 months gives it a 24.22%, and is 11.22% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.19% over the week and 4.91% over the month.

10x Genomics Inc (TXG) has around 1243 employees, a market worth around $5.73B and $590.98M in sales. Profit margin for the company is -37.80%. Distance from 52-week low is 43.44% and -23.75% from its 52-week high. The company has generated returns on investments over the last 12 months (-26.79%).

10x Genomics Inc quarterly earnings per share for the current quarter are estimated at -$0.36 with sales reaching $182.8M over the same period.The EPS is expected to shrink by -46.40% this year, but quarterly earnings will post 19.40% year-over-year. Quarterly sales are estimated to grow 17.00% in year-over-year returns.

384 institutions hold shares in 10x Genomics Inc (TXG), with institutional investors hold 93.84% of the company’s shares. The shares outstanding are 96.53M, and float is at 94.58M with Short Float at 6.05%. Institutions hold 91.67% of the Float.

The top institutional shareholder in the company is Vanguard Group Inc with over 8.55 million shares valued at $477.35 million. The investor’s holdings represent 8.27% of the TXG Shares outstanding. As of Jun 29, 2023, the second largest holder is Baillie Gifford and Company with 8.5 million shares valued at $474.88 million to account for 8.23% of the shares outstanding. The other top investors are FMR, LLC which holds 8.1 million shares representing 7.84% and valued at over $452.39 million, while Morgan Stanley holds 5.46% of the shares totaling 5.65 million with a market value of $315.39 million.

10x Genomics Inc (TXG) Insider Activity

A total of 12 insider transactions have happened at 10x Genomics Inc (TXG) in the last six months, with sales accounting for 12 and purchases happening 0 times. The most recent transaction is an insider sale by Saxonov Serge, the company’s Chief Executive Officer. SEC filings show that Saxonov Serge sold 4,000 shares of the company’s common stock on Jan 16 at a price of $45.24 per share for a total of $0.18 million. Following the sale, the insider now owns 0.86 million shares.

10x Genomics Inc disclosed in a document filed with the SEC on Dec 14 that Saxonov Serge (Chief Executive Officer) sold a total of 2,000 shares of the company’s common stock. The trade occurred on Dec 14 and was made at $55.03 per share for $0.11 million. Following the transaction, the insider now directly holds 0.85 million shares of the TXG stock.

Still, SEC filings show that on Nov 24, Saxonov Serge (Chief Executive Officer) disposed off 3,723 shares at an average price of $43.72 for $0.16 million. The insider now directly holds 847,446 shares of 10x Genomics Inc (TXG).

10x Genomics Inc (TXG): Who are the competitors?

One of the company’s main competitors (and peers) include Becton Dickinson & Co. (BDX) that is trading -2.87% down over the past 12 months.Enerplus Corp. (ERF) lies in the list of competitors of the 10x Genomics Inc and is -11.88% lower over the same period from TXGPacific Biosciences of California Inc. (PACB) is -34.89% down on the 1-year trading charts.